Spotlight On... Shire, Baxalta in late-stage talks on $32B tie-up: Bloomberg; Hikma wins FDA approval for surgery recovery drug; NICE does about-face on Merck's Ezetrol; and more...

Shire ($SHPG) is finally nearing the Baxalta ($BXLT) buyout it's long coveted, according to Bloomberg's sources. The two drugmakers are discussing a price between $46.50 and $48 per share, the news service reports, which would value the Illinois pharma at about $32 billion. A tie-up, Shire CEO Flemming Ornskov has said, would create a global rare-disease leader that can bring in $20 billion in sales by 2020. More from FiercePharma

> Hikma Pharmaceuticals has won FDA approval to market a drug used to enable patients to recover from surgery. Release

> U.K. cost-effectiveness gatekeepers have changed their tune when it comes to using Merck's ($MRK) hypercholesterolemia med Ezetrol on the National Health Service, reverting back to original guidelines published in 2007. More

And Finally... Some say the three-year cancer battle of Mary Pazdur, wife of FDA oncology chief Richard Pazdur, increased his willingness to quickly approve risky new therapies. More (sub. req.)

Suggested Articles

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.

The FDA wants to know what, exactly, is in a drug name—and whether it influences how the product is perceived. So it's launching a study to find out.

Horizon Therapeutics has notched an FDA approval for its rare eye disease med Tepezza (teprotumumab), a possible blockbuster drug in the making.